Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Poseida Therapeutics's peak revenue was $130.5M in 2022. The peak quarterly revenue was $116.3M in 2022(q3).
Poseida Therapeutics's revenue increased from $31.2m in 2021 to $64.7M currently. That's a 107.13% change in annual revenue.
| Fiscal year / year | Poseida Therapeutics revenue |
|---|---|
| 2021 | $31.2M |
| 2022 | $130.5M |
| 2023 | $64.7M |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2021 | - | - | - | $31.2M |
| 2022 | $1.4M | $2.7M | $116.3M | $10.1M |
| 2023 | $10.3M | $20.0M | $9.4M | $25.0M |
| 2024 | $28.1M | $26.0M | $71.7M | - |
Do you work at Poseida Therapeutics?
Is Poseida Therapeutics transparent about its revenue structure?
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 200 |
| Date Founded | 2014 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $64.7M |
| Net Income | -$64,002,000 |
| Tax Rate | -0.0% |
| Total Assets | $351,837,000 |
| Ticker | PSTX |
Poseida Therapeutics received early financing of $23.0M on 2015-12-23.
| Series | Round size | Date |
|---|---|---|
| Series A | $23M | 12/2015 |
| Series A | $11.2M | 08/2017 |
| Grant | $19.8M | 10/2017 |
| Series B | $30.5M | 04/2018 |
| Grant | $4.0M | 07/2018 |
| Series C | $142M | 04/2019 |
| Series D | $110M | 06/2020 |
| Investors | Security type |
|---|---|
| Malin Corporation PLC | Series A |
| Eric Ostertag | Series A |
| Malin Corporation PLC | Series A |
| Eric Ostertag | Series A |
| California Institute for Regenerative Medicine | Grant |
| Malin Corporation PLC | Series B |
| Vivo Capital | Series B |
| Tavistock Group | Series B |
| Longitude Capital | Series B |
| California Institute for Regenerative Medicine | Grant |
| Novartis | Series C |
| Rapha Capital Management LLC | Series C |
| Malin Corporation PLC | Series C |
| Vivo Capital | Series C |
| Perceptive Advisors | Series C |
| Longitude Capital | Series C |
| Pentwater Capital Management | Series C |
| Boxer Capital | Series C |
| Aisling Capital | Series C |
| SCHONFELD STRATEGIC ADVISORS | Series D |
| Adage Capital Management | Series D |
| Fidelity Management & Research Co LLC | Series D |
Poseida Therapeutics's top competitor, TCR² Therapeutics, earned an annual revenue of $661.1M.
Poseida Therapeutics's smallest competitor is BioEclipse Therapeutics with revenue of $78.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Allogene Therapeutics | - | $95,000 | 289 | - |
| Fate Therapeutics | - | $13.6M | 104 | - |
| Genprex | - | $45.0M | 7 | - |
| Leap Therapeutics | - | $1.5M | 30 | - |
| TCR² Therapeutics | - | $661.1M | 118 | - |
| Surface Oncology | - | $30.0M | 51 | - |
| BioEclipse Therapeutics | - | $78,000 | 6 | - |
| WindMIL Therapeutics | - | $530,000 | 30 | - |
Zippia gives an in-depth look into the details of Poseida Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Poseida Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Poseida Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Poseida Therapeutics. The data presented on this page does not represent the view of Poseida Therapeutics and its employees or that of Zippia.
Poseida Therapeutics may also be known as or be related to POSEIDA THERAPEUTICS, INC., Poseida Therapeutics, Poseida Therapeutics Inc and Poseida Therapeutics, Inc.